Evidence map›Paper›PMID 29190241›Full record

Trial reportRetina (Philadelphia, Pa.)2018

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.

Rocio Blanco-Garavito, Camille Jung, Joel Uzzan, Maddalena Quaranta-ElMaftouhi, Florence Coscas, Jose Sahel, Jean-Francois Korobelnik, Stéphane Béchet, Giuseppe Querques, Eric H Souied

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Retina (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Rocio Blanco-GaravitoService Universitarie d'Ophtalmologie, Hopital Intercommunal de Créteil, Créteil, France.
Camille JungService Universitarie d'Ophtalmologie, Hopital Intercommunal de Créteil, Créteil, France.
Joel UzzanClinique Mathilde, Rouen, France.
Maddalena Quaranta-ElMaftouhiClinique Rabelais, Lyon, France.
Florence CoscasService Universitarie d'Ophtalmologie, Hopital Intercommunal de Créteil, Créteil, France.
Jose SahelHôpital Quinze Vingts, Paris, France.
Jean-Francois KorobelnikService d'ophtalmologie, CHU de Bordeaux, University Bordeaux, ISPED, Bordeaux, France.
Stéphane BéchetAssociation Clinique et Thérapeutique Infantile du Val de Marne, Saint Maur, France.
Giuseppe QuerquesService Universitarie d'Ophtalmologie, Hopital Intercommunal de Créteil, Créteil, France.
Eric H SouiedService Universitarie d'Ophtalmologie, Hopital Intercommunal de Créteil, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab.

methodsMulticenter, prospective, nonrandomized clinical trial. One eye of patients presenting neovascular age-related macular degeneration with PED of more than 250 μm in height, with persistent fluid, was included. Patients had to have received at least six ranibizumab intravitreal injections during the 12 months before enrollment. Patients were switched from ranibizumab pro re nata to aflibercept (fixed regimen, 3 monthly intravitreal injections, and then Q6). Main outcome measure was change in PED height from baseline to Week 12 after switch. Secondary outcomes were best-corrected visual acuity and PED volume changes.

resultsEighty four patients were included. Mean delay between last ranibizumab intravitreal injection and switch was 44.7 days. Mean maximal PED height at baseline visit was 347 μm (±109) and reduced to a mean of 266 μm (±114) at Week 12 (P < 0.001) and 288.2 μm at Week 32 (P < 0.001). Mean PED volume was reduced from 1.3 mm to 0.98 mm at Week 12 (P < 0.001). Best-corrected visual acuity improved by 3.3 Early Treatment Diabetic Retinopathy Study letters at Week 32 (P = 0.003).

conclusionAflibercept switch therapy seems to be effective on large PED in patients previously treated with pro re nata ranibizumab.

Indexed as

Visual AcuityAgedAged, 80 and overAngiogenesis InhibitorsDrug SubstitutionFemaleFollow-Up StudiesHumansIntravitreal InjectionsMacula LuteaMaleMiddle AgedProspective StudiesRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID29190241
PMCPMC6250287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.